ACURX PHARMACEUTICALS, INC.

Analyst Reco. Acurx Pharmaceuticals, Inc.

Equities

ACXP

US00510M1045

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
2.04 ^USD	+3.03%		+22.89%	-46.74%

Apr. 04	Top Premarket Gainers	MT
Mar. 19	H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating	Mar. 19	MT
HC Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $14 From $13, Keeps Buy Rating	Dec. 15	MT
Acurx Reports 96% Clinical Cure Rate in Phase 2 Trial of Ibezapolstat in C. Difficile Infection; Shares Fall	Nov. 02	MT
Acurx Pharmaceuticals, Inc. Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. Difficile Infection	Nov. 02	CI
Maxim Raises Price Target on Acurx Pharmaceuticals to $10 From $7, Keeps Buy Rating	23-10-11	MT
HC Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $13 From $14, Keeps Buy Rating	23-08-15	MT
HC Wainwright Initiates Acurx Pharmaceuticals With Buy Rating, Sets $14 Price Target	22-12-19	MT
Alliance Global Starts Acurx Pharmaceuticals at Buy With $14 Price Target	22-10-20	MT
Maxim Group Starts Acurx Pharmaceuticals at Buy With $12 Price Target	21-11-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer